European Medicines Agency Makes Clinical Trial Advice Pilot Permanent Initiative
The EMA's ACT EU (Accelerating Clinical Trials in the European Union) advice pilot program will become a permanent service to support sponsors in preparing higher-quality clinical trial applications.
Key Details
The initiative strengthens cooperation across the European medicines regulatory network to improve clinical trial assessment processes and application quality.
Why It Matters
Permanent access to expert advice will help biotech and pharmaceutical companies navigate complex regulatory requirements more efficiently across Europe.
Context
The pilot program has demonstrated value in improving application quality and assessment efficiency, warranting its continuation as a permanent EMA service.
Source: The Pharma Letter. This article summarizes the linked reporting and distinguishes announced plans from demonstrated results.